Hyperuricemia - Pipeline Insight, 2024

Hyperuricemia - Pipeline Insight, 2024

DelveInsight’s, “Hyperuricemia - Pipeline Insight, 2024” report provides comprehensive insights about 12+ companies and 15+ pipeline drugs in Hyperuricemia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Hyperuricemia: Understanding

Hyperuricemia: Overview

Hyperuricemia is a common disorder that affects patients of all ages and genders. The most common manifestation of hyperuricemia is gout, which can be very painful and is amenable to treatment. Hyperuricemia is also associated with uric acid and calcium nephrolithiasis. Hyperuricemia affects about 38 million Americans, over 11% of the population, and the incidence is increasing worldwide. Most patients with hyperuricemia are asymptomatic, and the diagnosis requires a high degree of suspicion as serum uric acid levels are no longer routinely measured on serum blood panels. Patients with hyperuricemia who develop gout are usually best treated with a xanthine oxidase inhibitor like allopurinol. Depending on the urinary chemistry and stone type, allopurinol, potassium citrate, or both may be recommended in nephrolithiasis. Hyperuricemia, stemming largely from dietary purines and endogenous synthesis, contributes to roughly one-third of the body's daily serum uric acid production, with the remainder often arising from accelerated purine degradation or decreased excretion, as seen in various high cell turnover states and metabolic dysfunctions. While many individuals with hyperuricemia are asymptomatic, elevated uric acid levels can precipitate conditions like gout or nephrolithiasis. Furthermore, hyperuricemia and associated disorders, such as metabolic syndrome, diabetes mellitus, cardiovascular disease, hypertension, atherosclerosis, obesity, and chronic renal disease, are interconnected, potentially exacerbating one another's effects. Notably, the proportions of uric acid excretion through renal and gastrointestinal routes may fluctuate due to medication use or dysfunction within these systems.

Diagnostic procedures for hyperuricemia and related conditions involve various laboratory tests and imaging techniques. Elevated serum uric acid levels, typically exceeding 8 mg/dL, indicate hyperuricemia, with gender-specific variations. Urinalysis findings may include microscopic hematuria, uric acid crystals, and low urinary pH, suggesting nephrolithiasis. A 24-hour urine uric acid collection quantifies uric acid excretion, ideally below 600 mg/day on a low-purine diet, while levels exceeding 800 mg/d indicate hyperuricosuria. Additional tests such as complete blood count, metabolic panel, lipid profile, HbA1c, calcium, and phosphate assess associated disorders. Joint x-rays may aid in gout diagnosis, while renal ultrasounds or CT scans detect uric acid nephrolithiasis. Joint aspiration may confirm gout via identification of characteristic uric acid crystals under polarized microscopy.

Treatment for hyperuricemia typically involves medications that either decrease the production of uric acid or increase its excretion. Xanthine oxidase inhibitors, such as allopurinol, febuxostat, and topiroxostat, work by interfering with the enzyme responsible for converting purines into uric acid. Uricosuric agents, like benzbromarone, benziodarone, probenecid, and lesinurad, enhance the excretion of uric acid by reducing its reabsorption in the kidneys. Additionally, medications like nonsteroidal anti-inflammatory drugs (NSAIDs), colchicine, and corticosteroids can help manage symptoms of gout, a condition often associated with hyperuricemia. Lifestyle changes, such as a low-purine diet and moderation of alcohol consumption, are also recommended to help manage hyperuricemia

""Hyperuricemia- Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Hyperuricemia pipeline landscape is provided which includes the disease overview and Hyperuricemia treatment guidelines. The assessment part of the report embraces, in depth Hyperuricemia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Hyperuricemia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Hyperuricemia R&D. The therapies under development are focused on novel approaches to treat/improve Hyperuricemia.

Hyperuricemia Emerging Drugs Chapters

This segment of the Hyperuricemia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Hyperuricemia Emerging Drugs

ABP-671: Jiangsu Atom Bioscience

ABP-671, developed by Jiangsu Atom Bioscience and Pharmaceutical, is a small molecule under clinical development for treating gout associated with hyperuricemia. This drug is administered orally and acts by targeting the urate transporter 1 (URAT1) protein involved in uric acid reabsorption by the kidneys. ABP-671's mechanism of action involves inhibiting URAT1, which helps in reducing uric acid levels significantly and safely compared to existing gout treatments. This drug has shown promising results in clinical trials, demonstrating efficacy in maintaining serum uric acid levels within the recommended range for gout patients. Currently, the drug is in Phase III stage of its clinical trial for the treatment of hyperuricemia.

LR19074: LG Life Sciences

LR19074 is a novel non-purine selective inhibitor of Xanthine Oxidase (XO). XO is needed to successively oxidize both hypoxanthine and xanthine to uric acid. Hence, this agent reduces uric acid concentrations in serum by inhibiting the production of uric acid by XO inhibition. LC350189 has the potential to address the unmet clinical needs for safety and efficacy in gout treatment. LC350189 showed good systemic exposures and sUA lowering effects with no significant safety concerns in Korean and the U.S. healthy volunteers. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Hyperuricemia.

NC-2500: Nippon Chemiphar

NC-2500 is a novel advanced xanthine oxidoreductase (XOR) inhibitor, having potential to reduce the risk of gout flare, one of major issues of current treatments for gout, and make a difference in gout treatment. Currently, the drug is in Phase I stage of its clinical trial for the treatment of hyperuricemia.

Further product details are provided in the report……..

Hyperuricemia: Therapeutic Assessment

This segment of the report provides insights about the different Hyperuricemia drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Hyperuricemia

There are approx. 12+ key companies which are developing the therapies for Hyperuricemia. The companies which have their Hyperuricemia drug candidates in the most advanced stage, i.e. Phase III include, Jiangsu Atom Bioscience.

Phases

DelveInsight’s report covers around 15+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Hyperuricemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Intravenous

Subcutaneous

Parenteral

Topical

Molecule Type

Products have been categorized under various Molecule types such as

Recombinant fusion proteins

Small molecule

Monoclonal antibody

Peptide

Polymer

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Hyperuricemia: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Hyperuricemia therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Hyperuricemia drugs.

Hyperuricemia Report Insights

Hyperuricemia Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Hyperuricemia Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Hyperuricemia drugs?

How many Hyperuricemia drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Hyperuricemia?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Hyperuricemia therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Hyperuricemia and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Shanton Pharma

LG Chem

Sunshine Lake Pharma

InventisBio

Jiangsu Atom Bioscience and Pharmaceutical

Nippon Chemiphar

Key Products

SAP-001

LC350189

HEC93077

D-0120

ABP-671

NC-2500